ArticleBMC health services research2022

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.

Nicola Ferrante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.